Overview

Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin for First-Line Treatment of Patients With Advanced NSCLC Without Actionable Genomic Alterations

Status:
Recruiting

Trial end date:
2027-05-20

Target enrollment:

Participant gender:

Summary

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Cisplatin
Durvalumab
Paclitaxel
Pembrolizumab
Pemetrexed